Kintara Therapeutics, Inc. (KTRA)
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
$9.32M
Mr. Robert E. Hoffman B.B.A., CPA, CPA
3.00
San Diego, CA
Feb 22, 2013
-0.07
$-2.32
4.74
5.04
0.00%
-0.11
-0.00
0.17
0.00
5.04
-125.32%
-836.30%
Similar stocks (18)
Longboard Pharmaceuticals, Inc.
LBPH
scPharmaceuticals Inc.
SCPH
DiaMedica Therapeutics Inc.
DMAC
Seres Therapeutics, Inc.
MCRB
aTyr Pharma, Inc.
LIFE
Cellectar Biosciences, Inc.
CLRB
Dyadic International, Inc.
DYAI
Lumos Pharma, Inc.
LUMO
SAB Biotherapeutics, Inc.
SABS
Bolt Biotherapeutics, Inc.
BOLT
Lisata Therapeutics, Inc.
LSTA
GeoVax Labs, Inc.
GOVX
EOM Pharmaceuticals Holdings, Inc.
IMUC
Forte Biosciences, Inc.
FBRX
Kineta, Inc.
KA
Vaccinex, Inc.
VCNX
Fresh Tracks Therapeutics, Inc.
FRTX
Salarius Pharmaceuticals, Inc.
SLRX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (18)
Longboard Pharmaceuticals, Inc.
LBPH
scPharmaceuticals Inc.
SCPH
DiaMedica Therapeutics Inc.
DMAC
Seres Therapeutics, Inc.
MCRB
aTyr Pharma, Inc.
LIFE
Cellectar Biosciences, Inc.
CLRB
Dyadic International, Inc.
DYAI
Lumos Pharma, Inc.
LUMO
SAB Biotherapeutics, Inc.
SABS
Bolt Biotherapeutics, Inc.
BOLT
Lisata Therapeutics, Inc.
LSTA
GeoVax Labs, Inc.
GOVX
EOM Pharmaceuticals Holdings, Inc.
IMUC
Forte Biosciences, Inc.
FBRX
Kineta, Inc.
KA
Vaccinex, Inc.
VCNX
Fresh Tracks Therapeutics, Inc.
FRTX
Salarius Pharmaceuticals, Inc.
SLRX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%